Turner White CommunicationsAbout TWCSubscribeContact TWCHomeSearch
Hospital PhysicianJCOMSMPBRMsCart
Current Contents
Where We Are Indexed
Past Issue Archives
Clinical Communication
In Review
Editorial Board
Information for Authors
Author Form

Reprints, Permissions, & Copyright
Site Map
BACK ISSUE articles are $15 each.
International credit cards NOT accepted.

JCOM Paid Subscribers
user name:
Forgot password?

JCOM Abstract

J Clin Outcomes Manage 
2008 Jan;15(1):31-38
Biologic agents in the treatment of Crohn's disease
Wilson J, Brown SJ

Abstract Objective: To review the role of the biologic agents in therapy for Crohn’s disease, with particular emphasis on efficacy, indications for use, and impact on disease outcomes. Methods: Qualitative review of the literature and expert opinion. Results: A number of biologic agents are showing great promise as therapeutics for Crohn’s disease. The best established are the anti–tumor necrosis factor-a compounds, of which infliximab is the prototype. Traditionally, these agents have been reserved for patients who have not responded adequately to “conventional” therapy, although there is increased interest in using these potent medications early, with a view to altering the natural history and the outcomes of this disease. Challenges remain, including identifying patients who are most likely to benefit from such agents and minimizing potential toxicity. Conclusion: Biologic agents will continue to expand the therapeutic options in Crohn’s disease and lead to improved patient outcomes.

Clinical Review

Search the Turner White index to find abstracts of articles published in JCOM.

New issues are posted one month following publication of the printed journal.

View past issue archives:    2013    2012    2011    2010    2009    2008    2007
   2006    2005    2004    2003     2002     2001     2000     1999

Hospital Physician     JCOM     Seminars in Medical Practice
Hospital Physician Board Review Manuals
About TWC    Subscribe    Contact TWC    Home    Search   Site Map

Copyright © 2018, Turner White Communications
Updated 1/20/14 • jdw